Literature DB >> 15464197

Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression.

Joanne S Allard1, Yousef Tizabi, James P Shaffery, C Ovid Trouth, Kebreten Manaye.   

Abstract

Affective disorders often occur in combination with disrupted sleep-wake cycles and abnormal fluctuations in hypothalamic neurotransmitters. Hypocretin (orexin) is a hypothalamic neuropeptide linked to narcolepsy, a sleep-related disorder characterized by profound disturbances in the normal sleeping pattern and variable degrees of depression. Wistar-Kyoto (WKY) rats exhibit depressive characteristics and patterns of sleep disruption similar to that observed in depressed human patients. In this study we sought to determine whether the total number or the size of hypothalamic hypocretin neurons in WKY rats differ from their control, Wistar (WIS) rats. Immunocytochemical and stereological methods were applied to quantify hypocretin-1 containing neurons in the hypothalamus. The study revealed 18% fewer hypocretin-1 positive neurons as well as a 15% decrease in average neuronal soma size of hypocretin-1 producing cells in the hypothalamus of WKY rats compared to WIS rats. These findings support the view that reduced number or size of hypothalamic hypocretinergic neurons may underlie the disrupted sleep pattern associated with depressive characteristics in WKY rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464197     DOI: 10.1016/j.npep.2004.06.004

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  33 in total

Review 1.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 2.  Role of orexin in central regulation of gastrointestinal functions.

Authors:  Toshikatsu Okumura; Kaoru Takakusaki
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

3.  Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.

Authors:  Clarissa D Staton; Jazmine D W Yaeger; Delan Khalid; Fadi Haroun; Belissa S Fernandez; Jessica S Fernandez; Bali K Summers; Tangi R Summers; Monica Sathyanesan; Samuel S Newton; Cliff H Summers
Journal:  Neuropharmacology       Date:  2018-09-18       Impact factor: 5.250

Review 4.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

Review 5.  New directions for the treatment of depression: Targeting the photic regulation of arousal and mood (PRAM) pathway.

Authors:  Hannah E Bowrey; Morgan H James; Gary Aston-Jones
Journal:  Depress Anxiety       Date:  2017-05-10       Impact factor: 6.505

6.  Innervation of orexin/hypocretin neurons by GABAergic, glutamatergic or cholinergic basal forebrain terminals evidenced by immunostaining for presynaptic vesicular transporter and postsynaptic scaffolding proteins.

Authors:  Pablo Henny; Barbara E Jones
Journal:  J Comp Neurol       Date:  2006-12-01       Impact factor: 3.215

7.  Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency.

Authors:  S P Deats; W Adidharma; J S Lonstein; L Yan
Journal:  Neuroscience       Date:  2014-05-09       Impact factor: 3.590

8.  The effect of clomipramine on wake/sleep and orexinergic expression in rats.

Authors:  P Feng; Y Hu; D Li; D Vurbic; H Fan; S Wang; K P Strohl
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

Review 9.  The hypocretin system and psychiatric disorders.

Authors:  Fabio Pizza; Michele Magnani; Camilla Indrio; Giuseppe Plazzi
Journal:  Curr Psychiatry Rep       Date:  2014-02       Impact factor: 5.285

10.  Effects of rapid eye movement sleep deprivation on hypocretin neurons in the hypothalamus of a rat model of depression.

Authors:  Joanne S Allard; Yousef Tizabi; James P Shaffery; Kebreten Manaye
Journal:  Neuropeptides       Date:  2007-06-27       Impact factor: 3.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.